Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company. It engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treats several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.

Company profile
Ticker
PVCT
Exchange
Website
CEO
Bruce Horowitz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PROVECTUS PHARMACEUTICAL INC, PROVECTUS PHARMACEUTICALS INC, SPM GROUP INC, ZAMAGE DIGITAL IMAGING INC
SEC CIK
Corporate docs
IRS number
900031917
PVCT stock data
Press releases
Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia
17 Aug 22
Provectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress
30 Jun 22
Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
23 Jun 22
Investment data
Securities sold
Number of investors
Calendar
11 Aug 22
19 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Sep 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.03M | 2.03M | 2.03M | 2.03M | 2.03M | 2.03M |
Cash burn (monthly) | 149.47K | (no burn) | 359.33K | 362.3K | 292.63K | 55.32K |
Cash used (since last report) | 251.43K | n/a | 604.45K | 609.45K | 492.25K | 93.05K |
Cash remaining | 1.78M | n/a | 1.43M | 1.42M | 1.54M | 1.94M |
Runway (months of cash) | 11.9 | n/a | 4.0 | 3.9 | 5.3 | 35.1 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Jun 21 | Eric PHD Wachter | Series D-1 Convertible Preferred Stock Common Stock | Option exercise | Acquire M | No | No | 0 | 1,393,276 | 0 | 1,393,276 |
20 Jun 21 | Bruce Horowitz | Series D-1 Convertible Preferred Stock Common Stock | Option exercise | Acquire M | No | No | 0 | 38,473 | 0 | 38,473 |
20 Jun 21 | Pershing Edward | Series D-1 Convertible Preferred Stock Common Stock | Option exercise | Acquire M | No | No | 0 | 478,926 | 0 | 478,926 |
Institutional ownership, Q2 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 11K |
Total shares | 190.4K |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Home Federal Bank Of Tennessee | 100K | $6K |
Diversified Trust | 50K | $3K |
Captrust Financial Advisors | 20.4K | $1K |
Academy Capital Management | 20K | $1K |
Huntington National Bank | 1 | $0 |
Financial report summary
?Competition
Crinetics PharmaceuticalsContent analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
approach, Chief, Council, discretion, good, Harmonization, moved, practice, proportional, proposal, recommendation, renewed, reverse, split, stockholder, Technical
Removed:
activity, advisory, atopic, breast, carcinoma, cell, colorectal, entered, equivalent, Ewing, FDA, Food, gastrointestinal, GI, granted, HCC, head, hepatocellular, led, leukemia, liver, lung, mCRC, melanoma, metastatic, mNET, mUM, murine, neck, neuroblastoma, neuroendocrine, ocular, ODD, Orphan, osteosarcoma, reportedly, rhabdomyosarcoma, sarcoma, testicular, transformation, uveal
Financial reports
Current reports
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 22
8-K
Regulation FD Disclosure
22 Jun 22
8-K
Other Events
19 Apr 22
8-K
Amendments to Articles of Incorporation or Bylaws
4 Apr 22
8-K
Other Events
7 Sep 21
8-K
Entry into a Material Definitive Agreement
18 Aug 21
8-K
Submission of Matters to a Vote of Security Holders
28 Jun 21
8-K
Unregistered Sales of Equity Securities
24 Jun 21
8-K
Regulation FD Disclosure
23 Jun 21
8-K
Provectus Biopharmaceuticals Announces Change to Board of Directors
16 Jul 20
Registration and prospectus
D
$5M in debt / securities to be acquired, sold $200K, 1 investor
30 Aug 21
25-NSE
Exchange delisting
20 Apr 17
25-NSE
Exchange delisting
20 Apr 17
424B3
Prospectus supplement
5 Mar 17
424B3
Prospectus supplement
20 Feb 17
424B3
Prospectus supplement
8 Feb 17
424B4
Prospectus supplement with pricing info
30 Jan 17
S-1/A
IPO registration (amended)
20 Dec 16
Proxies
DEFA14A
Additional proxy soliciting materials
22 Jun 22
DEFA14A
Additional proxy soliciting materials
6 Jun 22
DEFA14A
Additional proxy soliciting materials
26 May 22
DEFA14A
Additional proxy soliciting materials
19 May 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
PRE 14A
Preliminary proxy
19 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
28 Apr 20
Other
CORRESP
Correspondence with SEC
26 Jan 17
EFFECT
Notice of effectiveness
26 Jan 17
CORRESP
Correspondence with SEC
24 Jan 17
CORRESP
Correspondence with SEC
18 Dec 16
UPLOAD
Letter from SEC
18 Dec 16
CORRESP
Correspondence with SEC
21 Nov 16
UPLOAD
Letter from SEC
15 Nov 16
CORRESP
Correspondence with SEC
31 Oct 16
UPLOAD
Letter from SEC
31 Oct 16
UPLOAD
Letter from SEC
23 Oct 16
Ownership
4
PROVECTUS BIOPHARMACEUTICALS / Edward Pershing ownership change
12 Aug 22
4
PROVECTUS BIOPHARMACEUTICALS / Heather Raines ownership change
18 Aug 21
SC 13D
PROVECTUS BIOPHARMACEUTICALS / WACHTER ERIC PHD ownership change
30 Jun 21
4
PROVECTUS BIOPHARMACEUTICALS / Heather Raines ownership change
22 Jun 21
4
PROVECTUS BIOPHARMACEUTICALS / Webster Bailey ownership change
22 Jun 21
4
PROVECTUS BIOPHARMACEUTICALS / Edward Pershing ownership change
22 Jun 21
4
PROVECTUS BIOPHARMACEUTICALS / ERIC PHD WACHTER ownership change
22 Jun 21
4
PROVECTUS BIOPHARMACEUTICALS / Bruce Horowitz ownership change
22 Jun 21
3/A
PROVECTUS BIOPHARMACEUTICALS / Bruce Horowitz ownership change
25 Nov 20
4
PROVECTUS BIOPHARMACEUTICALS / Heather Raines ownership change
12 Nov 20